HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert H Hyland Selected Research

ledipasvir

10/2020Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
1/2018Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
7/2017Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
1/2017Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
1/2016Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
11/2015Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
5/2014Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
3/2014Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
2/2014Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert H Hyland Research Topics

Disease

26Infections
12/2022 - 01/2013
13Fibrosis (Cirrhosis)
02/2019 - 05/2013
8Chronic Hepatitis C
03/2019 - 05/2013
6Nausea
11/2020 - 05/2013
5Hepatitis C
03/2015 - 01/2013
4Headache (Headaches)
01/2020 - 05/2013
4Fatigue
01/2017 - 05/2013
3COVID-19
01/2022 - 01/2020
3Arteriovenous Malformations (Arteriovenous Malformation)
12/2004 - 02/2003
2Disease Progression
01/2022 - 07/2017
2Cardiovascular Diseases (Cardiovascular Disease)
10/2020 - 01/2020
2Diarrhea
01/2017 - 01/2017
2Neutropenia
06/2013 - 05/2013
1Constipation
11/2020
1Respiratory Insufficiency (Respiratory Failure)
11/2020
1Chronic Renal Insufficiency
10/2020
1Hypertension (High Blood Pressure)
01/2020
1Hypokalemia
01/2020
1Hepatitis B
01/2018
1Sickle Cell Anemia (Hemoglobin S Disease)
09/2017
1Hemolytic Anemia
09/2017
1Cytopenia
09/2017
1Liver Neoplasms (Liver Cancer)
07/2017
1Gastroenteritis
01/2017
1Coinfection
01/2017
1Anemia
01/2017
1Bronchitis
01/2017
1HIV Infections (HIV Infection)
01/2017
1Mental Disorders (Mental Disorder)
02/2014
1Chills
05/2013
1Hereditary Hemorrhagic Telangiectasia
11/2003
1Hemorrhage
11/2003
1Gastrointestinal Hemorrhage (Hematochezia)
11/2003

Drug/Important Bio-Agent (IBA)

22SofosbuvirIBA
10/2020 - 01/2013
17Ribavirin (Virazole)FDA LinkGeneric
10/2020 - 01/2013
10NucleotidesIBA
01/2017 - 01/2013
9ledipasvirIBA
10/2020 - 02/2014
8InterferonsIBA
02/2019 - 01/2013
8sofosbuvir drug combination ledipasvirIBA
09/2017 - 02/2014
7Antiviral Agents (Antivirals)IBA
11/2020 - 03/2014
6Protease Inhibitors (Protease Inhibitor)IBA
01/2017 - 05/2013
5velpatasvirIBA
03/2019 - 01/2016
5sofosbuvir velpatasvir voxilaprevir drug combinationIBA
01/2019 - 01/2017
4peginterferon alfa-2a (Pegasys)FDA Link
06/2013 - 01/2013
3remdesivirIBA
01/2022 - 01/2020
3voxilaprevirIBA
01/2017 - 01/2016
2RNA (Ribonucleic Acid)IBA
12/2022 - 05/2013
2TabletsIBA
01/2018 - 01/2017
2GS-9669IBA
01/2016 - 03/2014
1Alanine Transaminase (SGPT)IBA
11/2020
1DNA-Directed RNA Polymerases (RNA Polymerase)IBA
11/2020
1CreatinineIBA
10/2020
1Proteins (Proteins, Gene)FDA Link
01/2017
1Drug CombinationsIBA
01/2016
1GS-9451IBA
01/2016
1NucleosidesIBA
03/2014
1UridineIBA
05/2013
1Technetium (Technetium 99m)IBA
11/2003

Therapy/Procedure

6Therapeutics
02/2019 - 01/2013
3Duration of Therapy
01/2017 - 01/2016
2Aftercare (After-Treatment)
07/2017 - 02/2003
1Artificial Respiration (Mechanical Ventilation)
11/2020
1Retreatment
01/2019
1Contraindications
02/2014
1Therapeutic Embolization
12/2004
1Blood Transfusion (Blood Transfusions)
11/2003
1Catheters
11/2003